C Kearon, SR Kahn, G Agnelli, S Goldhaber, … - Chest, 2008 - Am Coll Chest Phys Page 1. DOI 10.1378/chest.08-0658 2008;133;454S-545S Chest Gary E. Raskob and
Anthony J. Comerota Clive Kearon, Susan R. Kahn, Giancarlo ... Cited by 211 - Related articles - All 16 versions
- ►ahajournals.org S Wan, DJ Quinlan, G Agnelli, JW Eikelboom - Circulation, 2004 - Am Heart Assoc Methods and Results— We performed a meta-analysis of all randomized trials
comparing thrombolytic therapy with heparin in patients with acute pulmonary
embolism. Eleven trials, involving 748 patients, were included. Compared ... Cited by 162 - Related articles - BL Direct - All 10 versions
- ►annals.org [PDF] W Lim, F Dentali, JW Eikelboom, MA Crowther - Annals of internal medicine, 2006 - Am Coll Physicians Purpose: To compare levels of anti-Xa heparin and risk for major bleeding in
LMWH-treated patients with a creatinine clearance of 30 mL/min or less versus
those with a creatinine clearance greater than 30 mL/min by using standard ... Cited by 102 - Related articles - BL Direct - All 5 versions
JI Weitz, SM Bates - Journal of Thrombosis and Haemostasis, 2005 - interscience.wiley.com Summary. The limitations of heparin and warfarin have prompted the development
of new anticoagulant drugs for prevention and treatment of venous and arterial
thromboembolism. Novel parenteral agents include synthetic analogs of the ... Cited by 84 - Related articles - BL Direct - All 4 versions
- Free from Publisher SM Bates, IA Greer, I Pabinger, S Sofaer, J … - Chest, 2008 - chestjournal.chestpubs.org This article discusses the management of venous thromboembolism (VTE) and
thrombophilia, as well as the use of antithrombotic agents, during pregnancy and
is part of the American College of Chest Physicians Evidence-Based Clinical ... Cited by 72 - Related articles - All 10 versions
- ►annals.org [PDF] V Snow, A Qaseem, P Barry, ER Hornbake, JE … - Annals of internal medicine, 2007 - Am Coll Physicians Background: New treatments are available for treatment of venous
thromboembolism. ... Purpose: To review the evidence on the efficacy of
interventions for treatment of deep venous thrombosis (DVT) and pulmonary ... Cited by 67 - Related articles - BL Direct - All 23 versions
SM Bates, JI Weitz - British journal of haematology, 2006 - critcaremed.org Currently available anticoagulants include heparin, low-molecular weight
heparin, fondaparinux and warfarin. Despite advances with low-molecular weight
heparin and fondaparinux, the currently available agents have limitations ... Cited by 51 - Related articles - Cached - BL Direct - All 11 versions
- ►asnjournals.org [PDF] W Lim, DJ Cook, MA Crowther - Journal of the American Society of Nephrology, 2004 - Am Soc Nephrol Abstract. Low molecular weight heparins (LWMH) are the preferred initial
treatment for many thromboembolic disorders but are renally excreted and
relatively contraindicated in patients with renal failure because of ... Cited by 48 - Related articles - All 4 versions
I Greer, BJ Hunt - British journal of haematology, 2005 - pt.wkhealth.com Low molecular weight heparin (LMWH) is now the most commonly used anticoagulant
for prophylaxis and treatment of venous thromboembolism in pregnancy and the
puerperium in the UK. The reliable pharmacokinetics of LMWHs and their long ... Cited by 43 - Related articles - All 6 versions
